Objective: To determine the efficacy of Mitomycin C (MMC) in symptomatic improvement in outcome in patients of chronic Rhinosinusitis (CRS) after Endoscopic Sinus Surgery (ESS/ FESS) using SNOT-20 and its domains.
Study design: Randomized Clinical Trial.Materials and Methods: Total 150 patients between" May 2011 to July 2014 with clinical and CT features of chronic rhino sinusitis, not responding to maximal medical treatment, were subjected to endoscopic sinus surgery (ESS/FESS).75 patients were included in Group A (Interventional-MMC) and 75 patients in group B (Control-Saline). There were 30 unilateral and 45 bilateral, thus 120 operative sides in each group. Follow up visits were done at weekly for first two weeks and then at 1 st , 2 nd and 3 rd month and subjective parameters evaluated included total score and individual symptom score of 4 symptoms-Facial pain/pressure, Nasal block, Discharge and Hyposmia, SNOT-20 score and its 4 domains-Rhinologic domain, Ear & facial domain, Sleep and Psychologic domains.
Results:The symptomatic improvement found in present study was slightly better in Group-A than Group-B. There was significant difference between the group A & B with respect to change in SNOT total score from pre to post-operative period (p<0.001). Group A showed better improvement in rhinologic domain, whereas group B showed better improvement in ear and facial domain. In sleep and psychologic domains, both the groups showed similar post operative improvement. (p.0.05).
Conclusion:Symptomatically, MMC shown better improvement in relieving nasal obstruction and facial pain but did not had much role in nasal discharge and hyposmia. The symptomatic outcome signifies the efficacy of FESS without any significant role of MMC.